EUCTR2010-021556-25-IT进行中（未招募）不适用
Phase III, randomized, open-label, multicenter evaluation of efficacy and tolerability `of Ialuril (sodium hyaluronate-chondroitin sulfate) vs. dimethyl sulfoxide (DMSO) in women with interstitial cystitis / painful bladder syndrome (IC / BPS)AscoltaTrascrizione foneticaDizionario - Visualizza dizionario dettagliato - IBSA 01-2010
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- IBSA
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Female patients aged greater than or equal to 18 years
- •2. Diagnosis of IC / BPS resistant to first-line treatment of non-invasive or early observation
- •3. Presence of pain (pelvic pressure or discomfort) in relation to the bladder accompanied by at least one other urinary symptom such as persistent urge to urinate or frequent urination at least six months
- •4. Discomfort or pain during intercourse
- •5. Women of childbearing potential must have negative pregnancy test
- •6. Subjects in the four previous months have not participated in other trials.
- •7. Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •. Patients younger than 18 years
- •2. Male patients
- •3. Patients who are pregnant and / or lactation
- •4. Confusable Diseases as the main cause of urinary symptoms (
- •5. Previous intravesical treatment for IC / BPS.
研究者
相似试验
进行中（未招募）
1 期
Keeping RAASi treatment with optimal potassium controlHyperkalemia in patients with chronic kidney disease (CKD) and heart failure historyMedDRA version: 21.1Level: LLTClassification code 10020647Term: HyperkalemiaSystem Organ Class: 100000004861MedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.0Level: LLTClassification code 10019285Term: Heart failure, unspecifiedSystem Organ Class: 100000004849EUCTR2020-003229-47-ESInstituto de Investigación Sanitaria INCLIVA78
进行中（未招募）
1 期
A randomized, open-label, multicenter, phase III, study comparing efficacy and tolerability of the intensified variant ‘dose-dense/dose-intense ABVD’ with an interim PET response-adapted ABVD program at first line therapy in advanced-stage classical Hodgkin Lymphoma (HL).Advanced stage (IIB-IV) Hodgkin Lymphoma.MedDRA version: 20.0Level: LLTClassification code 10020328Term: Hodgkin's lymphomaSystem Organ Class: 100000004864EUCTR2016-002509-21-ITFONDAZIONE ITALIANA LINFOMI ONLUS500
进行中（未招募）
不适用
An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapiesmetastatic renal cell carcinomaMedDRA version: 14.1Level: PTClassification code 10038410Term: Renal cell carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-015459-25-ATovartis Pharma Services AG550
进行中（未招募）
1 期
An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapiesmetastatic renal cell carcinomaMedDRA version: 14.1Level: PTClassification code 10038410Term: Renal cell carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-015459-25-BEovartis Pharma Services AG550
进行中（未招募）
不适用
An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapiesmetastatic renal cell carcinomaMedDRA version: 14.0Level: PTClassification code 10038410Term: Renal cell carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-015459-25-DEovartis Pharma Services AG550